{"id":"https://openalex.org/W56569517","doi":null,"title":"Technology evaluation: gemtuzumab ozogamicin, Celltech Group.","display_name":"Technology evaluation: gemtuzumab ozogamicin, Celltech Group.","publication_year":2000,"publication_date":"2000-12-01","ids":{"openalex":"https://openalex.org/W56569517","mag":"56569517","pmid":"https://pubmed.ncbi.nlm.nih.gov/11249747"},"language":"en","primary_location":{"id":"pmid:11249747","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11249747","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in molecular therapeutics","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065183683","display_name":"Ion Niculescu\u2010Duvaz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"I Niculescu-Duvaz","raw_affiliation_strings":["CRC Centre for Cancer Therapeutics, Institute for Cancer Research, Sutton, Surrey, SM2 5NG, UK. ion@icr.ac.uk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CRC Centre for Cancer Therapeutics, Institute for Cancer Research, Sutton, Surrey, SM2 5NG, UK. ion@icr.ac.uk","institution_ids":["https://openalex.org/I142947616"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5065183683"],"corresponding_institution_ids":["https://openalex.org/I142947616"],"apc_list":null,"apc_paid":null,"fwci":1.3443,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.78859626,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"2","issue":"6","first_page":"691","last_page":"6"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.006899999920278788,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemtuzumab-ozogamicin","display_name":"gemtuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8970000147819519},{"id":"https://openalex.org/keywords/cd33","display_name":"CD33","score":0.7770000100135803},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8259999752044678},{"id":"https://openalex.org/keywords/accelerated-approval","display_name":"accelerated approval","score":0.5410000085830688},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.5260000228881836},{"id":"https://openalex.org/keywords/sales-forecasting","display_name":"sales forecasting","score":0.5230000019073486},{"id":"https://openalex.org/keywords/pharmaceutical-market","display_name":"pharmaceutical market","score":0.4429999887943268},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.3799999952316284}],"concepts":[{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.982194185256958},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7367440462112427},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.4946253001689911},{"id":"https://openalex.org/C3017489713","wikidata":"https://www.wikidata.org/wiki/Q4686866","display_name":"Advisory committee","level":2,"score":0.4579938054084778},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3632969558238983},{"id":"https://openalex.org/C176290653","wikidata":"https://www.wikidata.org/wiki/Q21114013","display_name":"CD33","level":4,"score":0.3378857374191284},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.2816610336303711},{"id":"https://openalex.org/C3116431","wikidata":"https://www.wikidata.org/wiki/Q31728","display_name":"Public administration","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.0},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000079982","descriptor_name":"Gemtuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000617","descriptor_name":"Aminoglycosides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001709","descriptor_name":"Biotechnology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015470","descriptor_name":"Leukemia, Myeloid, Acute","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:11249747","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11249747","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in molecular therapeutics","raw_type":"Clinical Trial"},{"id":"mag:56569517","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11249747","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2320121145","https://openalex.org/W40024774","https://openalex.org/W2006420057","https://openalex.org/W2028350949","https://openalex.org/W283152677","https://openalex.org/W4254170770","https://openalex.org/W2937156809","https://openalex.org/W1821781403","https://openalex.org/W1981354237","https://openalex.org/W2790209799"],"abstract_inverted_index":{"Gemtuzumab":[0],"ozogamicin":[1],"(CMA-676)":[2],"is":[3,174,178],"a":[4,10,38,252],"cytotoxic":[5,154],"drug":[6],"(calichaemicin)":[7],"linked":[8],"to":[9,49,58,103,180,203],"human":[11],"monoclonal":[12],"antibody":[13],"that":[14,92],"targets":[15],"CD33,":[16],"and":[17,23,28,80,100,140,177],"which":[18],"has":[19],"been":[20],"jointly":[21],"developed":[22],"launched":[24,160],"by":[25,170,183],"Celltech":[26,237],"Group":[27],"the":[29,50,72,84,108,125,133,164,184],"Wyeth-Ayerst":[30,45],"Research":[31],"division":[32],"of":[33,97,110,135,137,186,196,221,233,255],"American":[34],"Home":[35],"Products":[36],"as":[37],"treatment":[39,109,134],"for":[40,56,107,130,132,153],"acute":[41],"myeloid":[42],"leukemia":[43],"(AML).":[44],"submitted":[46,182],"an":[47],"NDA":[48],"US":[51,85,165],"FDA":[52,73,126],"in":[53,81,112,142,163,175,200,207,211,219],"October":[54],"1999":[55],"approval":[57,106,129],"treat":[59],"AML":[60,111,147],"patients":[61,113,136],"who":[62,114,148],"have":[63,115],"relapsed":[64,116],"after":[65],"initial":[66,118],"chemotherapy":[67,119,155],"[346494].":[68],"In":[69,122,189,225],"January":[70,212],"2000,":[71,83,124,191,213],"assigned":[74],"CMA-676":[75,131,158],"Priority":[76],"Review":[77],"status":[78],"[351745],":[79],"March":[82],"FDA's":[86],"Oncologic":[87],"Drugs":[88],"Advisory":[89],"Committee":[90],"voted":[91],"there":[93],"was":[94,159],"sufficient":[95],"evidence":[96],"improved":[98],"safety":[99],"acceptable":[101],"efficacy":[102],"support":[104],"accelerated":[105],"following":[117],"[360113],":[120],"[361883].":[121],"May":[123],"gave":[127],"final":[128],"60":[138],"years":[139],"over":[141],"first":[143],"relapse":[144],"with":[145,236],"CD33+":[146],"are":[149],"not":[150],"considered":[151],"candidates":[152],"[367212],":[156],"[367215].":[157],"(as":[161],"Mylotarg)":[162],"on":[166,248],"1":[167],"June":[168],"2000":[169,187],"AHP.":[171,241],"An":[172],"EMAA":[173],"preparation":[176],"expected":[179],"be":[181],"end":[185],"[382163].":[188],"September":[190],"Merill":[192],"Lynch":[193],"predicted":[194,216,230],"sales":[195,218,232],"2.9":[197],"million":[198,205,223,257],"Pounds":[199,206],"2002,":[201],"rising":[202],"17.9":[204],"2004":[208],"[383742],":[209],"while":[210],"Lehman":[214,228],"Brothers":[215,229],"peak":[217,231],"excess":[220],"US$200":[222],"[360128].":[224],"December":[226],"1999,":[227],"US$150":[234],"million,":[235],"receiving":[238],"royalties":[239],"from":[240],"Possible":[242],"first-line":[243],"therapy":[244],"could":[245],"follow":[246],"depending":[247],"further":[249],"studies,":[250],"creating":[251],"potential":[253],"market":[254],"US$300":[256],"[352078].":[258]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}